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Pharmacokinetics and tolerability 
of NSC23925b, a novel 
P-glycoprotein inhibitor: preclinical 
study in mice and rats
Yan Gao1,2, Jacson K. Shen1, Edwin Choy1, Zhan Zhang3, Henry J. Mankin1, 
Francis J. Hornicek1 & Zhenfeng Duan1
Overexpression of P-glycoprotein (Pgp) increases multidrug resistance (MDR) in cancer, which 
greatly impedes satisfactory clinical treatment and outcomes of cancer patients. Due to unknown 
pharmacokinetics, the use of Pgp inhibitors to overcome MDR in the clinical setting remains elusive 
despite promising in vitro results. The purpose of our current preclinical study is to investigate the 
pharmacokinetics and tolerability of NSC23925b, a novel and potent P-glycoprotein inhibitor, in 
rodents. Plasma pharmacokinetic studies of single-dose NSC23925b alone or in combination with 
paclitaxel or doxorubicin were conducted in male BALB/c mice and Sprague-Dawley rats. Additionally, 
inhibition of human cytochrome P450 (CYP450) by NSC23925b was examined in vitro. Finally, the 
maximum tolerated dose (MTD) of NSC23925b was determined. NSC23925b displayed favorable 
pharmacokinetic profiles after intraperitoneal/intravenous (I.P./I.V.) injection alone or combined with 
chemotherapeutic drugs. The plasma pharmacokinetic characteristics of the chemotherapy drugs 
were not affected when co-administered with NSC23925b. All the animals tolerated the I.P./I.V. 
administration of NSC23925b. Moreover, the enzymatic activity of human CYP450 was not inhibited by 
NSC23925b. Our results demonstrated that Pgp inhibitor NSC23925b exhibits encouraging preclinical 
pharmacokinetic characteristics and limited toxicity in vivo. NSC23925b has the potential to treat 
cancer patients with MDR in the future.
P-glycoprotein (Pgp, MDR1, or ABCB1) has been identified as a pivotal modulator in a network of cellular fac-
tors that introduces multidrug resistance (MDR)1,2. The presence of Pgp overexpression in neoplasms is either 
inherent or acquired by the administration of chemotherapy. Increased expression of Pgp can induce MDR by 
preventing sufficient intracellular accumulation of a large number of anticancer drugs that are chemically, struc-
turally, and functionally unrelated3. Initially, Pgp was recognized as merely responsible for the failure of conven-
tional cytotoxic agents (e.g., vinblastine, doxorubicin, and paclitaxel). However, the actions of this transporter can 
contribute to resistance to a broad range of more than 300 compounds4,5. In addition, targeted therapy drugs are 
also substrates of this energy-dependent efflux pump6,7. For instance, constitutive overexpression of Pgp results in 
acquired resistance to the small molecule kinase inhibitor imatinib8. Therefore, suppression of Pgp expression and 
inhibition of its function have become promising strategies to overcome the development of MDR.
Ongoing efforts have focused on identifying more potent and specific compounds for the reversal of 
Pgp-mediated MDR9. These inhibitors can be produced by de novo synthesis using a variety of combinatorial 
chemistry approaches and a database of structural activity relationships for drug-Pgp interactions. A series of 
Pgp modulators or inhibitors have been demonstrated to be able to dramatically increase the chemosensitivity 
to common Pgp substrates in drug-resistant cell lines. Unfortunately, in spite of those promising in vitro results, 
almost none of the Pgp inhibitors have achieved clinical success over the years3,10,11. In general, these compounds, 
such as verapamil, cyclosporine A, valspodar (PSC833, Amdray), and biricodar (VX710, INCEL), were beset by 
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poor potency, off-target effects, and toxicity12,13. A common strategy to overcome MDR is the co-administration 
of Pgp inhibitors with chemotherapy drugs. The failure to reverse MDR using Pgp inhibitors in clinic may also be 
attributed to adverse drug-drug interactions and unpredicted pharmacokinetic issues. For example, valspodar has 
shown undesirable pharmacokinetic behavior by interacting with paclitaxel, doxorubicin, etoposide, and mitox-
antrone14,15. Additionally, similar pharmacokinetic profiles were observed in a potent Pgp inhibitor, tariquidar. 
Co-administration of tariquidar with vinorelbine demonstrated limited clinical activity16,17. Clearly, the clinical 
application of a new biologically active compound can be significantly constrained by its absorption, distribution, 
metabolism, excretion, and toxicity parameters within the body. Pharmacological studies are indispensable dur-
ing Pgp inhibitor discovery and development.
NSC23925 has been identified as a potent MDR mitigator via selectively targeting Pgp by screening over 
2000 small molecule compounds in the National Cancer Institute (NCI) Diversity Set library18,19. Four distinct 
isomers of NSC23925 exist as a result of two chiral centers of the structure, known as NSC23925a, NSC23925b, 
NSC23925c, and NSC23925d. Isomer NSC23925b shows the most potent bioactivities in reversing MDR. 
Previous studies have indicated that NSC23925b is able to reverse paclitaxel, doxorubicin, and mitoxantrone 
resistance in a human breast cancer MDR cell line and a human colon cancer MDR cell line. It is much more 
potent (10- to 60-fold) than that of the known drug resistance reversing agents verapamil or CsA18,19. Additionally, 
NSC23925b is also able to prevent the emergence of anticancer drug resistance in vivo and in vitro by suppressing 
Pgp function, as shown in ovarian cancer and osteosarcoma20,21. Even though NSC23925b holds therapeutic value 
in the treatment of MDR-dependent cancers, its pharmacokinetic behavior is largely unknown. Currently, there 
are no pharmacokinetic or toxicity data for NSC23925b.
The purposes of the present study are to characterize the in vivo pharmacokinetics of isomer NSC23925b in 
rodents, to evaluate in vitro human Cytochrome P450 (CYP450) inhibitory properties, and to investigate the 
preclinical maximum tolerated dose and safety profile of this small molecular compound (Relative molecular 
mass Mr = 421.35).
Results
Plasma pharmacokinetic profile of NSC23925b after I.P./I.V. injection alone or combined 
with chemotherapeutic drug. The mean plasma concentration versus time profiles of NSC23925b (I.P.: 
5.00 mg/kg, I.V.: 2.50 mg/kg) when administered alone or with paclitaxel/doxorubicin are shown in Fig. 1, and 
the corresponding pharmacokinetic parameters are summarized in Tables 1 and S1. In brief, peak concentra-
tions were achieved at approximately 1.50 ± 0.866 hours (mice) and 2.17 ± 3.32 hours (rats) post-I.P. dose of 
NSC23925b. NSC23925b concentrations declined biexponentially after the Tmax with a mean terminal elimina-
tion half-life of 8.69 ± 4.18 hours for mice and 9.24 ± 3.77 hours for rats. Following I.V. administration to mice, 
mean clearances (CL) were 24.6 ± 1.96 mL·kg−1·min−1, 25.3 ± 0.984 mL·kg−1·min−1, and 22.8 ± 0.938 mL·k-
g−1·min−1 for NSC23925b alone, NSC23925b with paclitaxel, and NSC23925b with doxorubicin, respectively. 
There were no significant changes among other pharmacokinetic parameters; for example, in the case of AUC0-inf 
(the area under the plasma concentration versus time curve), NSC23925b only was 1701 ± 130 h·ng·mL−1, 
Figure 1. Plasma pharmacokinetic profile of NSC23925b after intraperitoneal injection/intravenous 
injection (I.P./I.V.) administration. (A) Plasma concentration-time profile of NSC23925b in male BALB/c 
mice at 5.00 mg/kg (I.P.) alone, 2.50 mg/kg (I.V.) alone, and co-administered with paclitaxel/doxorubicin; (B) 
single-dose plasma pharmacokinetics of NSC23925b in male Sprague-Dawley rats following 5.00 mg/kg (I.P.) 
alone, 2.50 mg/kg (I.V.) alone, and co-administered with paclitaxel/doxorubicin. Data: mean ± SD of each time 
point.
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combination NSC23925b and paclitaxel was 1649 ± 65.6 h·ng·mL−1, combination NSC23925b and doxorubicin 
and 1827 ± 73.8 h·ng·mL−1. The peak plasma NSC23925b concentrations for both I.V. and I.P. were observed at 
the earliest time point (15 minutes after administration). The concentrations of NSC23925b in plasma were above 
the lower limit of quantification throughout the sampling period. Similar to the results obtained in mice, the three 
pharmacokinetic profiles of NSC23925 alone and co-administered with either paclitaxel or doxorubicin also 
displayed a parallel trend within the rats.
The pharmacokinetic characteristics of chemotherapeutic drugs (paclitaxel, doxorubicin) were 
not influenced when co-administrated with NSC23925b. The mean plasma concentration versus 
time profiles of paclitaxel and doxorubicin during I.V. administration combined with or without NSC23925b are 
shown in Fig. 2. The overall plasma concentration-time profiles for the two chemotherapeutic drugs demonstrate 
a rapid decline in concentrations. Moreover, for either paclitaxel or doxorubicin, as well as either mice or rats, 
when the drugs were used alone or in combination with NSC23925b, these curves almost overlapped. The cor-
responding pharmacokinetic parameters are summarized in Tables 2 and S2. Paclitaxel concentrations in mice 
displayed a mean terminal elimination half-life of 1.33 ± 0.28 hours when dosed alone, and 1.54 ± 0.115 hours 
while dosed together with NSC23925b. Doxorubicin concentrations in mice showed a similar mean terminal 
elimination half-life, 10.7 ± 3.29 hours (dosed alone) vs. 12.8 ± 1.91 hours (dosed together with NSC23925b). 
With respect to the CL of paclitaxel and doxorubicin, similar values were obtained: 33.2 ± 3.12 mL·kg−1·min−1 
(dosed alone) compared with 39.8 ± 6.46 mL·kg−1·min−1 (dosed together with NSC23925b) for paclitaxel, 
and 18.2 ± 1.93 mL·kg−1·min−1 (dosed alone) compared with 14.6 ± 1.53 mL·kg−1·min−1 (dosed together with 
NSC23925b) for doxorubicin. However, some of the pharmacokinetic parameters of chemotherapeutic drug pacl-
itaxel, such as Vdss, t1/2, Kel, MRTIV, and AUMC0-inf were altered when combined with NSC23925b in rats. Vdss can 
change independent of clearance. As a result, a decrease of Vdss in the absence of alteration in clearance resulted 
in shorter t1/2 and larger Kel.
NSC23925b did not inhibit the activity of human CYP450. In vitro CYP450 inhibition evaluation of 
NSC23925b was conducted in the HLM reaction system for the CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 
enzymes, respectively. Thirty μ M phenacetin (substrate of CYP1A2), 70 μ M bupropion (substrate of CYP2B6), 
10 μ M paclitaxel (substrate of CYP2C8), 10 μ M diclofenac (substrate of CYP2C9), 35 μ M S-mephenytoin (sub-
strate of CYP2C19), 10 μ M bufuralol (substrate of CYP2D6), 5 μ M midazolam, and 80 μ M testosterone (sub-
strates of CYP3A4) were treated with HLM in the presence of their specific inhibitors or NSC23925b. The 
substrate-CYP450 enzyme reactions and reference inhibitors are shown in Table 3. A sigmoid-shaped curve 
(Log(inhibitor) vs. Response-Variable slope) was fitted to the data and the IC50 was calculated using GraphPad 
Prism software. The concentration-effect plots of NSC23925b and particular reference inhibitor against the 
CYP450 enzyme are displayed in Fig. 3. As expected, specific CYP inhibitors showed significant inhibitory activ-
ity after incubating with the substrates (Table 3). Although NSC23925b was found to be a moderate inhibitor 
Pharmacokinetic 
Parameters
BALB/c Mice SD Rats
I.P. 5.00 mg/kg I.V. 2.50 mg/kg
I.V. 2.50 mg/kg
I.P. 5.00 mg/kg I.V. 2.50 mg/kg
I.V. 2.50 mg/kg
Combined 
with Paclitaxel 
5.00 mg/kg
Combined with 
Doxorubicin 
2.00 mg/kg
Combined 
with Paclitaxel 
5.00 mg/kg
Combined with 
Doxorubicin 
1.00 mg/kg
Kel(h−1) 0.0922 ± 0.0402 0.140 ± 0.0172 0.185 ± 0.0281 0.114 ± 0.0199 0.0826 ± 0.0280 0.0785 ± 0.00486 0.0842 ± 0.0102 0.0711 ± 0.00389
t1/2(h)* 8.69 ± 4.18 5.01 ± 0.661 3.81 ± 0.569 6.17 ± 0.985 9.24 ± 3.77 8.86 ± 0.541 8.32 ± 1.07 9.77 ± 0.535
AUC0-t (h·ng·mL−1) 3364 ± 197 1636 ± 114 1624 ± 75.9 1716 ± 101 1386 ± 173 766 ± 51.9 725 ± 49.0 979 ± 109
AUC0-inf (h·ng·mL−1) 3983 ± 819 1701 ± 130 1649 ± 65.6 1827 ± 73.8 1994 ± 855 902 ± 57.4 837 ± 77.1 1191 ± 133
AUMC0-t (h·h·ng·mL−1) 25329 ± 4810 9893 ± 1299 9122 ± 493 10730 ± 314 13328 ± 5611 5504 ± 317 5110 ± 574 7447 ± 855
AUMC0-inf (h·h·ng·mL−1) 50744 ± 36083 11945 ± 2141 9862 ± 253 14400 ± 1089 38450 ± 36415 10502 ± 642 9163 ± 2323 15529 ± 2132
CL (mL·kg−1·min−1) / 24.6 ± 1.96 25.3 ± 0.984 22.8 ± 0.938 / 46.3 ± 3.06 50.1 ± 4.75 35.3 ± 4.11
MRTIV(h) / 6.99 ± 0.836 5.98 ± 0.166 7.90 ± 0.788 / 11.7 ± 0.512 10.9 ± 1.89 13.0 ± 0.964
VdSS(L·kg−1) / 10.3 ± 0.808 9.09 ± 0.565 10.8 ± 1.44 / 32.4 ± 3.06 32.4 ± 3.87 27.6 ± 3.42
tmax(h) 1.50 ± 0.866 / / / 2.17 ± 3.32 / / /
Cmax(ng·mL−1) 298 ± 56.1 / / / 128 ± 44.3 / / /
F (%) 117.1 ± 24.06 / / / 110.6 ± 47.4 / / /
Table 1.  Plasma pharmacokinetic parameters of NSC23925b (Data provided as mean ± SD). 
Abbreviations: AUC0-t, area under the concentration-time curve calculated from zero up to the last measured 
concentration; AUC0-inf, area under the concentration-time curve extrapolated from zero up to infinity; 
AUMC0-t, area under the first moment of the concentration-time curve from zero up to the last measured 
concentration; AUMC0-inf, area under the first moment of the concentration-time curve from zero up to infinity; 
CL, clearance; Cmax, maximum plasma concentration; F, bioavailability; MRTIV, mean residence time of a drug 
administered intravenously; I.P., intraperitoneal injection; I.V., intravenous injection; Kel, elimination rate 
constant; tmax, time to maximum observed concentration; t1/2, elimination half life; Vdss, volume of distribution 
at steady-state. *P < 0.05.
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on CYP2B6 and CYP2D6 mediated metabolism of bupropion and bufuralol, respectively, the IC50 values of 
NSC23925b were still much higher than the reference inhibitors clopidogrel and quinidine (8.589 versus 0.914, 
1.407 versus 0.048). Moreover, the IC50s of NSC23925b on CYP450 mediated metabolism of other standard sub-
strates were found to be > 10 μ M.
The I.P./I.V. administration of NSC23925b was well-tolerated by BALB/c mice and SD rats. 
During the pharmacokinetic study, I.P. or I.V. administrations of NSC23925b with or without paclitaxel/doxo-
rubicin were generally tolerated by all the rodents. Specifically, all 180 mice and 24 rats were administered the 
aforementioned intended doses; no treatment-related clinical signs were observed from the animals. BALB/c 
mice had body weights ranging from 17.80 to 22.80 g; SD rats had body weights ranging from 225 to 255 g. A total 
of 80 (40 female, 40 male) mice and 80 (40 female, 40 male) rats were used in the sighting study and main study 
on assessing the MTD of NSC23925b. For I.P. injection, three of five female mice survived after administering 
93.75 mg/kg NSC23925b, while all five male mice tolerated the dosage of 68.80 mg/kg; one of five female rats died 
when treated with 47.20 mg/kg, and all male rats were still in good status at 33.10 mg/kg dose (Table 4). In regard 
to the I.V. dosing route, the 24.70 mg/kg dosage did not significantly influence the health conditions of any of the 
female and male mice, while female and male rats generally tolerated as much as 47.20 mg/kg and 38.80 mg/kg 
NSC23925b respectively, with the exception of one female rat that was moribund (Table 4).
Discussion
NSC23925b is a novel compound that reverses and prevents Pgp-mediated MDR in cancer cells18,19,22–24. In the 
current study, we have determined the plasma pharmacokinetics of NSC23925b after I.P or I.V administration 
in mice and rats. Following the I.P. 5.00 mg/kg dose and the I.V. administration of a single 2.50 mg/kg dose of 
NSC23925b, the highest concentrations in plasma were observed at approximately 1–2 hours after I.P. injection 
and 5 min after I.V. injection. Rapid decline in concentration of NSC23925b was followed by a steady elimination 
in mice and rats. NSC23925b also showed high volumes of distribution at a steady state (> 9 L/kg). The demon-
strated concentration-time profiles were analogous to some reported drug resistance inhibitors25–27. The peak 
plasma inhibitor concentrations were observed at the earliest time point especially after I.V. injection, and the 
concentrations of detected inhibitor in plasma were above the lower limit of quantification throughout the sam-
pling period. In addition, the pharmacokinetics of classic chemotherapeutic drugs, paclitaxel and doxorubicin, 
were not affected when combined with NSC23925b. Although it seems that some pharmacokinetic parameters, 
such as Kel, t1/2, MRTIV, and Vdss, of the chemotherapeutic drug paclitaxel were altered when combined with 
NSC23925b in rats, these results may be explained as changes in volume of distribution were independent of 
changes in clearance28. Further study of pharmacokinetics and NSC23925b in large animals, such as in dogs or 
Figure 2. Plasma pharmacokinetic profile of paclitaxel and doxorubicin after intravenous injection (I.V.) 
alone or co-administration with NSC23925b. Plasma concentration-time course of paclitaxel in male BALB/c 
mice at a single 5.00 mg/kg dose (A), and in male Sprague-Dawley rats at a single 5.00 mg/kg dose (B); plasma 
concentration-time curves of doxorubicin in male BALB/c mice at a single 2.00 mg/kg dose (C), and in male 
Sprague-Dawley rats at a single 1.00 mg/kg dose (D). Data: mean ± SD of each time point.
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monkeys, may be needed to validate these changes. Moreover, whether NSC23925b could be extrapolated to 
restore targeted therapy drugs sensitivity requires further investigation.
Human CYP450 is a family of enzymes responsible for the essential biotransformation processes of endoge-
nous molecules and xenobiotics29. Alteration of CYP450 enzymatic activity, such as inhibition or induction, can 
remarkably impact the pharmacokinetics and thereby the pharmacodynamics of drugs. Particularly, enzyme inhi-
bition by a specific drug is the main cause of adverse side-effects22,30. For that purpose, CYP450 inhibition data 
are useful in designing strategies for investigating clinical drug-drug interaction studies. The IC50 values of drugs, 
which represent the concentration of inhibitor required for 50% inhibition of enzyme activity, are determined in 
order to estimate the inhibition potential toward all corresponding CYPs. IC50 values of > 10 μ M, 1–10 μ M, and 
< 1 μ M are considered weak, moderate, and potent inhibitors, respectively31. Based on the in vitro NSC23925b 
CYP450 inhibition assay results, the IC50s of this compound for human CYP450 enzymes (CYP1A2, 2C8, 2C9, 
2C19, and 3A4) were more than 10 μ M and could be regarded as a weak inhibitor. In addition, NSC23925b was 
considered as moderate inhibitor for CYP2B6 and CYP2D6 (the IC50s were between 1–10 μ M). Even though 
the IC50 of NSC23925b for CYP2D6 was 1.407 μ M, it was still approximately 30 times higher than the relative 
reference inhibitor (0.048 μ M). Moreover, co-administration may result in inhibition of the metabolism of one or 
both compounds through inhibition of a specific CYP450 enzyme. NSC23925b has again been confirmed to not 
act as an inhibitor of any CYP450 enzymes due to its weak influence on the plasma pharmacokinetic characters of 
paclitaxel/doxorubicin in the abovementioned study. Therefore, it may be deduced that NSC23925b will not alter 
pharmacokinetics, distribution, or clearance of the commonly used chemotherapeutic drugs.
In general, all treatments were well-tolerated by the animals across the pharmacokinetic study and the MTD 
assay. Adverse events were generally mild, either from the known effects of the chemotherapeutic drugs studied 
or other unrelated toxic reactions, and were resolved without intervention. Particularly, critical negative con-
sequences of paclitaxel include neurotoxicity, hypersensitivity, hematologic toxicity, cardiac disturbances, and 
Pharmacokinetic 
Parameters
Paclitaxel Doxorubicin
BALB/c Mice SD Rats BALB/c Mice SD Rats
I.V. 5.00 mg/kg
Combined with 
NSC23925b 
2.50 mg/kg I.V. 5.00 mg/kg
Combined with 
NSC23925b 
2.50 mg/kg I.V. 2.00 mg/kg
Combined with 
NSC23925b 
2.50 mg/kg I.V. 1.00 mg/kg
Combined with 
NSC23925b 
2.50 mg/kg
Kel(h−1) 0.535 ± 0.102 0.453 ± 0.0343 0.0602 ± 0.00420 0.129 ± 0.00797† 0.0682 ± 0.0184 0.0548 ± 0.00810 0.0695 ± 0.0214 0.0486 ± 0.00290
t1/2 (h) 1.33 ± 0.28 1.54 ± 0.115 11.6 ± 0.777 5.40 ± 0.346† 10.7 ± 3.29 12.8 ± 1.91 10.5 ± 2.76 14.3 ± 0.870
AUC0-t (h·ng·mL−1) 2504 ± 238 2104 ± 386 4200 ± 492 5677 ± 624 207 ± 9.76 158 ± 29.3 89.7 ± 35.6 105 ± 5.16
AUC0-inf (h·ng·mL−1) 2523 ± 244 2134 ± 381 4608 ± 517 5767 ± 609 272 ± 53.7 218 ± 28.5 117 ± 32.5 139 ± 8.44
AUMC0-t (h·h·ng·mL−1) 2728 ± 356 2642 ± 484 13231 ± 1265 12697 ± 484 1470 ± 309 1217 ± 180 446 ± 282 706 ± 51.6
AUMC0-inf(h·h·ng·mL−1) 2911 ± 400 2947 ± 425 29892 ± 4245 15585 ± 149† 4157 ± 2493 3766 ± 987 1318 ± 527 2233 ± 231
CL (mL·kg−1·min−1) 33.2 ± 3.12 39.8 ± 6.46 18.2 ± 1.93 14.6 ± 1.53 126 ± 22.4 155 ± 19.2 151 ± 43.1 120 ± 7.57
MRTIV (h) 1.16 ± 0.147 1.39 ± 0.0829 6.50 ± 0.853 2.72 ± 0.304† 14.6 ± 5.71 17.3 ± 4.17 11.1 ± 2.41 16.1 ± 0.771
VdSS(L·kg−1) 2.31 ± 0.428 3.33 ± 0.680 7.13 ± 1.34 2.40 ± 0.515† 105 ± 19.8 161 ± 47.9 97.1 ± 19.5 116 ± 3.57
Table 2.  Plasma pharmacokinetic parameters of paclitaxel and doxorubicin (Data provided as 
mean ± SD). Abbreviations: AUC0-t, area under the concentration-time curve calculated from zero up to 
the last measured concentration; AUC0-inf, area under the concentration-time curve extrapolated from zero 
up to infinity; AUMC0-t, area under the first moment of the concentration-time curve from zero up to the 
last measured concentration; AUMC0-inf, area under the first moment of the concentration-time curve from 
zero up to infinity; CL, clearance; MRTIV, mean residence time of a drug administered intravenously; I.P., 
intraperitoneal injection; I.V., intravenous injection; Kel, elimination rate constant; t1/2, elimination half life; 
Vdss, volume of distribution at steady-state. †P < 0.05.
Cytochrome 
P450Isoforms
Substrate/ 
Concentration (μM) Substrate Reaction
Compound IC50 (μM)
NSC23925b Reference Inhibitors
CYP1A2 Phenacetin/30 O-deethylation > 10 0.006 a-Naphthoflavone 
CYP2B6 Bupropion/70 hydroxylation 8.589 0.914 Clopidogrel 
CYP2C8 Paclitaxel/10 6α -hydroxylation > 10 1.248 Nicardipine 
CYP2C9 Diclofenac/10 4-hydroxylation > 10 0.635 Sulfaphenazole 
CYP2C19 S-Mephenytoin/35 4-hydroxylation > 10 4.081 Omeprazole 
CYP2D6 Bufuralol/10 O-demethylation 1.407 0.048 Quinidine 
CYP3A4 Midazolam/5 1-hydroxylation > 10 0.015 Ketoconazole 
Testosterone/80 6ß-hydroxylation > 10 0.022 Ketoconazole 
Table 3.  Comparison of inhibitive potentials IC50 between NSC23925b and reference inhibitors on 
cytochrome P450s (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4).
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gastrointestinal tract symptoms, while the major side-effect of doxorubicin is cardiotoxicity, which can lead to 
cardiomyopathy and congestive heart failure23,24. However, during the pharmacokinetic study, the combination 
of NSC23925b did not aggravate the adverse reactions of the two drugs in their in vivo safe dose range. Moreover, 
according to the MTD results, the rodents tolerated the dosage of NSC23925b from 24.70 mg/kg to 93.75 mg/kg, 
which was much higher than the 2.50–5.00 mg/kg dose used in previous pharmacokinetic analyses and investiga-
tions18,20,32. Hence, a wide range of dosages of NSC23925b can be safely utilized in preclinical studies, which may 
offer a hopeful perspective for its application in Phase I/II clinical study.
Figure 3. Comparison of inhibitive potentials between NSC23925b and reference inhibitors on human 
cytochrome (CYP) 450s (CYP1A2, 2B6, 2C8, 2C19, 2D6, and 3A4). The concentration-effect sigmoid-
shaped plots of NSC23925b and particular reference inhibitor against the respective CYP450 enzyme, CYP1A2 
(A), CYP2B6 (B), CYP2C8 (C), CYP2C19 (D), CYP2D6 (E), and CYP3A4 (F,G). The red triangles and line 
represent NSC23925b, and the black dots and line indicates the reference inhibitors. “NC” stands for normal 
control (saline).
Animals Route Dose
Number of 
Death
Number of 
Exposure
BABL/c Mice
I.P. 93.75 mg/kg (Female) 2 5
I.P. 68.80 mg/kg (Male) 0 5
I.V. 24.70 mg/kg (Female) 0 5
I.V. 24.70 mg/kg (Male) 0 5
SD Rats
I.P. 47.20 mg/kg (Female) 1 5
I.P. 33.10 mg/kg (Male) 0 5
I.V. 47.20 mg/kg (Female) 1 5
I.V. 38.80 mg/kg (Male) 0 5
Table 4.  Determination of maximum tolerated dose (MTD) of NSC23925b in rodents. Abbreviations: I.P., 
intraperitoneal injection; I.V., intravenous injection.
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In conclusion, NSC23925b is a potential Pgp inhibitor with favorable preclinical pharmacokinetics and lim-
ited toxicity. The data in the current study will provide insights on Phase I/II clinical trials evaluating NSC23925b 
alone or combined with chemotherapeutics. Moreover, we have crystallized isomers of NSC23925b and collected 
the crystal structure data. These results will also facilitate the initiation of an ongoing docking model to under-
stand the underlying mechanism of how NSC23925b inhibits the function of Pgp.
Methods
Drug and chemical information. The NSC23925b isomer (molecular weight: 384.9 g/mol) was syn-
thesized by Chengdu ChemPartner Co., Ltd. with a purity of > 99%. NSC23925b was initially dissolved in 5% 
dimethyl sulfoxide (DMSO), and then diluted in normal saline to the concentration as required. Final vehicle 
concentrations were 1–5% DMSO and 95–99% saline. Paclitaxel (6 mg/mL) and doxorubicin (2 mg/mL) were 
supplied by Teva Pharmaceuticals (Sellersville, PA) and APP Pharmaceuticals (Schaumburg, IL), respectively. 
Both chemotherapeutic drugs were diluted with normal saline for injection. DMSO was purchased from Sigma-
Aldrich (St. Louis, MO). Clinical use saline was obtained from Jiling Dubang Pharmaceutical Co., Ltd. The dose 
levels of NSC23925b, paclitaxel, and doxorubicin were determined based on available data from previous related 
studies18–21. The particular dosage of each chemical is described in the following specific experiments. All other 
reagents utilized in this study were provided by PharmaLegacy Laboratories (Shanghai, China). Data on handling 
and disposal instructions together with any available safety information are retained on file at PharmaLegacy 
Laboratories.
Animals. Naive BALB/c mice and Sprague-Dawley rats (SD rats) were ordered from Shanghai SLAC 
Laboratory Animal Co. Ltd (Shanghai, China). All the animals were specific pathogen free and approximately 6–8 
weeks old when they arrived at PharmaLegacy Laboratories. The mice were 18–22 g, and the rats were 200–250 g 
upon receipt. A health inspection was performed on each animal to include evaluation of the coat, extremities, 
and orifices. Each animal was also examined for any abnormal signs in posture or movement. The animals were 
housed in the PharmaLegacy Laboratories vivarium in clear polycarbonate plastic cages. The adaptation to the 
environment for the animals was no less than seven days. Animals were observed daily for signs of ill health 
and general reaction to the treatments. The procedures that were applied on animals in this study have been 
approved by the Massachusetts General Hospital Subcommittee on Research Animal Care (protocol number 
2013N000121) and PharmaLegacy Laboratories Institutional Animal Care and Use Committee. The methods 
were carried out in accordance with the approved guidelines. Any moribund animals were euthanized with CO2 
inhalation followed by cervical dislocation for humane reasons. All surviving animals placed on study were euth-
anized at their scheduled study termination. Extra animals obtained for this study, but not placed on study, were 
returned to PharmaLegacy vivarium for other uses, such as training programs.
In vivo preclinical pharmacokinetic analyses. Pharmacokinetic studies of NSC23925b, paclitaxel, and 
doxorubicin were performed in male BALB/c mice and SD rats. Specifically, 5.00 mg/kg (dose concentration: 
0.50 mg/mL) and 2.50 mg/kg (dose concentration: 0.25 mg/mL) NSC23925b were administered by intraperitoneal 
and intravenous (I.P. and I.V.) injection, respectively; 5.00 mg/kg (dose concentration: 0.50 mg/mL) paclitaxel was 
administered to all murine via I.V.; and 2.00 mg/kg (dose concentration: 0.20 mg/mL) doxorubicin for mice and 
1.00 mg/kg (dose concentration: 0.10 mg/mL) doxorubicin for rats were administered through I.V.
After dosing, blood samples were collected at different time points for each group. The time points for the I.P. 
dosing groups were at pre-dose and post dose (15, 30 min, and then 1, 2, 4, 6, 8, and 24 hours) of the test chem-
icals; for the I.V. dosing groups, time points were at pre-dose and post dose (5, 15, 30 min, and then 1, 2, 4, 6, 8 
and 24 hours) of the test agents. Three animals were used for each time point. Approximately 800 μ L of blood was 
collected via orbital vein (a source of collecting sufficient volume of venous blood) from each anesthetized mouse 
by isoflurane, and 200 μ L of blood was collected from the cannula implanted in the jugular vein. The catheter 
was implanted when the blood sample was collected at the first time point. Next, the blood was transferred to a 
prepared tube containing sodium heparin anticoagulant and mixed briefly by gentle inversion three to four times. 
The target and actual time of blood sampling were recorded relative to the time of dosing. Samples were placed 
on wet ice immediately after collection. Within 1 hour after collection, plasma was separated by centrifugation 
at 4,000 rpm for 10 minutes at 4 °C. The plasma was protected from light and stored at − 80 °C until analyzed by 
liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) for quantification.
Standards were prepared in blank murine plasma that was in a tube containing sodium heparin anticoagulant 
covering the nominal concentration range of 2–1,000 ng/mL (NSC23925b), 2.50–1,000 ng/mL (paclitaxel), and 
1–1,000 ng/mL (doxorubicin). Using the data from the standards, calibration curves were generated for each ana-
lytical batch. Aliquots of 10.0 μ L of samples, calibraton curve samples, and QC samples were supplemented with 
100 μ L of precipitant (a mixture of acetone and acetonitrile (30:70)). After vortexing for 3 min and centrifuging at 
12,000 rpm for 3 min, 75.00 μ L of the supernatant was transferred into a 96-well microplate with an equal volume 
of water. The 10 μ L mixture solution was injected for LC-MS/MS analysis. The specific instrumental conditions of 
LC-MS/MS bioanalysis of NSC23925b, paclitaxel, and doxorubicin are listed in Table 5. The estimation of phar-
macokinetic parameters is shown in Tables 1, 2, S1 and S2.
In vitro human liver microsomes (HLM)-LC-MS human CYP450 inhibition study of 
NSC23925b. To understand the potential drug-drug interactions of NSC23925b, the HLM-LC-MS CYP450 
inhibition assay was performed in vitro. This assay used a cocktail of drug-probe substrates that are specific to 
each isozyme with HLM and LC-MS detection33,34. Each test article and reference inhibitor was dissolved in 40% 
DMSO and 60% acetonitrile (ACN) mixture. Specifically, 0.20 mg/mL HLM, test compound set, and reference 
inhibitor solution were added into the designated 96-well polypropylene plate. Substrates were then added to 
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their respective well containing the compound/HLM solution to start the reaction. The drug-probe substrate con-
centrations and estimated individual CYP enzyme concentrations from HLM are shown in Table 3. Nicotinamide 
adenine dinucleotide phosphate (NADPH) cofactor (66.70 mg NADPH in 10 mL 100 mM phosphate buffer, 
pH 7.4) was added into each well. After incubating for 5 min for 3A4; 10 min for 1A2, 2C8, 2C9, and 2D6; and 
45 min for 2C19 at a 37 °C incubator, the reactions were terminated by addition of 120 μ L of ACN to denature 
the protein. The solution was centrifuged at 4 °C for 30 min at 3,700 rpm and the supernatant was transferred for 
LC-MS analysis. The concentrations of the metabolites were determined from standard curves using commer-
cially available metabolite standards. Compounds were tested in triplicate. The half maximal inhibitory concen-
tration (IC50) values were determined by plotting the metabolite formation over the logarithm of the compound 
concentration using Prism 5.0 software (GraphPad Software Inc., San Diego, CA).
Determination of maximum tolerated dose (MTD) of NSC23925b and evaluation of acute 
safety profiles in rodents. The MTD determination assay was composed of sighting study and main 
study26,35–37. For the sighting study of the determination maximum tolerable dose (MTD) of NSC23925b, one of 
each animal (one female rat, one male rat, one female mouse, and one male mouse) was used at each I.V. and I.P. 
injection dose level. The starting dose was selected from the fixed dose levels (5, 50, 500, 2000 mg/kg) as a dose 
expected to produce evident toxicity. The first animal was dosed and observed. Time of appearance, degree, and 
lasting/recovery time of signs were recorded in details. Afterwards, animals were observed twice on the dosing 
day and then changed to daily observation. The observation lasted at least 14 days. If the first animal died or 
appeared impaired, the second animal received a middle dose of the two doses and vice versa. The sighting study 
was completed when a decision on the starting dose for the main study was made.
During the main study, a total of five animals of one sex were used for each dose level investigated. The five 
animals were made up of one animal from the sighting study dosed at the selected dose level together with an 
additional four animals. Each group received one of the fixed doses by I.V. and I.P. based on the sighting study. If 
the first animal died or appeared impaired, the second animal received a middle dose of the two doses and vice 
versa.
Animals were fasted overnight prior to dosing. Following the period of fasting, the animals were weighed and 
the dose was calculated according to the body weight. After the animals were administrated a dose volume of 
10 mL/kg, food was withheld for another 3–4 hours. Individual weights of animals were determined shortly before 
the test substance was administered and twice weekly thereafter. Weight changes were calculated and recorded. 
Animals injected with saline were the control group for the weight alteration.
Data collection and statistical methods. Results were expressed as mean ± SD and 95% confidence 
interval. Data collection was performed using Analyst version 1.4 from Applied Biosystems. All pharmacokinetic 
parameters of NSC23925b, paclitaxel, and doxorubicin after I.V. or I.P. administrations in mice/rats were calcu-
lated based on the plasma concentrations obtained in this study by non-compartmental analysis by WinNonLin 
software (Version 5.01, Pharsight, Inc., Mountain View, CA). The data were also analyzed using Prism 5.0 soft-
ware. Statistical significance was determined using independent two-tailed Student t-tests and one-way ANOVA 
for independent data. Differences of P < 0.05 were regarded as significant for all statistical analyses.
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